Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Erectile Dysfunction 2Carcinoma 2Urinary Incontinence 1Pyridoxine-dependent epilepsy 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

apatinib 3sintilimab 2Taxes 2Paclitaxel 2Oxaliplatin 2Hyperthermic Intraperitoneal Chemotherapy 2Albumin-Bound Paclitaxel 2trastuzumab deruxtecan 1taxane 1pembrolizumab 1durvalumab 1disitamab vedotin 1cabozantinib 1XELOX 1Tegafur 1Tadalafil 1SHR-1701 1S 1 (combination) 1Platinum 1Magnetic Resonance Spectroscopy 1Injections 1Gastrectomy 1Drug Therapy 1Drug Evaluation 1Docetaxel 1Cytoreduction Surgical Procedures 1Cisplatin 1Capecitabine 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastric Adenocarcinoma × Tadalafil × Clear all
NCT05709574 2025-10-16

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

University of Arizona

Phase 2 Recruiting
10 enrolled
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡